台新藥股份有限公司
台新藥股份有限公司是一家臨床階段的生物製藥公司，在台灣研發眼科、腫瘤及抗感染領域的候選藥物。研發管線包括：APP13007（用於術後疼痛及眼部炎症，處於臨床三期）、TSY-110（抗體藥物複合體）、TSY-0210（抗藥性感染抗生素）、APP13002（治療感染性眼疾）及 MPT0E028（治療固體腫瘤）。公司與 Eyenovia, Inc. 簽署合作開發協議。公司成立於 2010 年，總部位於台灣台北市。
今日下跌 2.86%。該股 RSI(6) 為 67.2，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、60日、120日均線。短中期均線呈多頭排列，趨勢偏多。KD 指標中性（K=66.6）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -129 | 0 | -1 | -130 |
| 09-23 | +162 | 0 | -12 | +150 |
| 09-22 | +7 | 0 | 0 | +7 |
| 09-21 | +14 | 0 | +2 | +16 |
| 09-18 | -55 | 0 | +16 | -39 |
| 09-17 | +37 | 0 | 0 | +37 |
| 09-16 | -1 | 0 | +2 | +1 |
| 09-15 | -7 | 0 | 0 | -7 |
| 09-14 | -1 | 0 | 0 | -1 |
| 09-11 | -20 | 0 | -3 | -23 |
| 09-10 | +14 | 0 | +2 | +16 |
| 09-09 | -13 | 0 | 0 | -13 |
| 09-08 | 0 | 0 | +1 | +1 |
| 09-07 | +8 | 0 | 0 | +8 |
| 09-04 | +29 | 0 | -1 | +28 |
| 09-03 | +95 | 0 | +1 | +96 |
| 09-02 | +88 | 0 | 0 | +88 |
| 09-01 | -3 | 0 | +1 | -2 |
| 08-31 | -19 | 0 | 0 | -19 |
| 08-28 | -23 | 0 | 0 | -23 |
| 08-27 | -2 | 0 | 0 | -2 |
| 08-26 | +5 | 0 | +2 | +7 |
| 08-25 | +12 | 0 | 0 | +12 |
| 08-24 | -6 | 0 | 0 | -6 |
| 08-21 | -3 | 0 | 0 | -3 |
| 08-20 | +4 | 0 | 0 | +4 |
| 08-19 | -15 | 0 | 0 | -15 |
| 08-18 | -36 | 0 | 0 | -36 |
| 08-17 | 0 | 0 | +3 | +3 |
| 08-14 | -11 | 0 | 0 | -11 |
| 08-13 | -11 | 0 | +1 | -10 |
| 08-12 | -13 | 0 | 0 | -13 |
| 08-11 | -7 | 0 | 0 | -7 |
| 08-10 | -4 | 0 | 0 | -4 |
| 08-07 | +1 | 0 | 0 | +1 |
| 08-06 | -62 | 0 | +1 | -61 |
| 08-05 | -10 | 0 | 0 | -10 |
| 08-04 | -50 | 0 | -4 | -54 |
| 08-03 | +2 | 0 | -6 | -4 |
| 07-31 | +26 | 0 | +3 | +29 |
| 07-30 | +20 | 0 | -2 | +18 |
| 07-29 | -3 | 0 | +2 | -1 |
| 07-28 | +119 | 0 | +1 | +120 |
| 07-27 | +68 | 0 | +1 | +69 |
| 07-24 | +31 | 0 | -1 | +30 |
| 07-23 | -19 | 0 | 0 | -19 |
| 07-22 | -4 | 0 | -6 | -10 |
| 07-21 | -7 | 0 | 0 | -7 |
| 07-20 | +56 | 0 | 0 | +56 |
| 07-17 | -25 | 0 | +1 | -24 |
| 07-16 | -9 | 0 | +1 | -8 |
| 07-15 | +33 | 0 | +5 | +38 |
| 07-14 | -3 | 0 | +6 | +3 |
| 07-13 | -28 | 0 | 0 | -28 |
| 07-09 | +23 | 0 | 0 | +23 |
| 07-08 | +10 | 0 | -2 | +8 |
| 07-07 | +31 | 0 | -2 | +29 |
| 07-06 | -87 | 0 | +4 | -83 |
| 07-03 | +91 | 0 | -2 | +89 |
| 07-02 | -23 | 0 | 0 | -23 |
| 07-01 | +13 | 0 | +2 | +15 |
| 06-30 | +30 | 0 | 0 | +30 |
| 06-29 | +58 | 0 | 0 | +58 |
| 06-26 | -65 | 0 | -3 | -68 |
| 06-25 | +14 | 0 | 0 | +14 |
| 06-24 | +48 | 0 | 0 | +48 |
| 06-22 | -39 | 0 | -2 | -41 |
| 06-18 | +3 | 0 | +3 | +6 |
| 06-17 | -18 | 0 | +2 | -16 |
| 06-16 | +30 | 0 | -4 | +26 |
| 06-15 | +129 | 0 | +3 | +132 |
| 06-12 | -2 | 0 | -1 | -3 |
| 06-10 | +1 | 0 | -5 | -4 |
| 06-09 | -41 | 0 | -2 | -43 |
| 06-08 | +15 | 0 | +1 | +16 |
| 06-04 | +60 | 0 | +2 | +62 |
| 06-03 | +8 | 0 | -2 | +6 |
| 06-02 | -71 | 0 | -1 | -72 |
| 06-01 | +37 | 0 | -1 | +36 |
| 05-29 | +22 | 0 | 0 | +22 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/08 | 0 | - | - |
| 2026/07 | 0 | -100.0% | - |
| 2026/06 | 68 萬 | -71.1% | - |
| 2026/05 | 235 萬 | - | -50.7% |
| 2026/04 | 0 | -100.0% | - |
| 2026/03 | 4411 萬 | +3272.6% | - |
| 2026/02 | 131 萬 | - | +120.2% |
| 2026/01 | 0 | -100.0% | - |
| 2025/12 | 323 萬 | - | - |
| 2025/11 | 0 | - | -100.0% |
| 2025/10 | 0 | -100.0% | -100.0% |
| 2025/09 | 91 萬 | - | -79.0% |